



DAFTAR PUSTAKA

- Aherne, N. J. and Murphy, B. M. (2018) 'Radiation-induced gliomas', *Critical Reviews in Oncogenesis*, 23(1–2), pp. 113–118. doi: 10.1615/CritRevOncog.2018025740.
- Appin, C. L. *et al.* (2013) 'Glioblastoma with oligodendroglioma component (GBM-O): Molecular genetic and clinical characteristics', *Brain Pathology*, 23(4), pp. 454–461. doi: 10.1111/bpa.12018.
- Byreddy, V., Sreelakshmi, I. and N, E. (2018) 'Role of Ki 67 Immunostaining as an Adjunct to Differentiate Low Grade and High Grade Gliomas', *IOSR Dent Med Sci (IOSR-JDMS)*, 17(7), pp. 11–17. doi: 10.9790/0853-1707161117.
- Cohen, A. L., Holmen, S. L. and Colman, H. (2013) 'IDH1 and IDH2 mutations in gliomas', *Current Neurology and Neuroscience Reports*, 13(5), pp. 1–7. doi: 10.1007/s11910-013-0345-4.
- Collins, V. P., Jones, D. T. W. and Giannini, C. (2015) 'Pilocytic astrocytoma: pathology, molecular mechanisms and markers', *Acta Neuropathologica*. Springer Berlin Heidelberg, 129(6), pp. 775–788. doi: 10.1007/s00401-015-1410-7.
- Deng, L. *et al.* (2018) 'Association between IDH1/2 mutations and brain glioma grade', *Oncology Letters*, 16(4), pp. 5405–5409. doi: 10.3892/ol.2018.9317.
- Devi, S., De Padufile:///C:/Users/ASUS/Downloads/07-048769.pdf, M. and Kalal, I. (2018) 'Study of Histomolecular Classification of Glioma-Integrating Histology and Molecular Analysis in the Diagnosis of Brain Tumors', *Indian Journal of Neurosurgery*, 07(02), pp. 129–134. doi: 10.1055/s-0038-1668469.
- Dwianingsih, E. K. *et al.* (2017) 'Correlation between grading and IDH1 mutation in Indonesian glioma', *Journal of the Neurological Sciences*. Elsevier B.V., 381(2017), pp. 386–387. doi: 10.1016/j.jns.2017.08.3306.
- Gladson, C. L., Prayson, R. A. and Liu, W. M. (2010) 'The pathobiology of glioma tumors', *Annual Review of Pathology: Mechanisms of Disease*, 5(Cmv), pp. 33–50. doi: 10.1146/annurev-pathol-121808-102109.
- De Groot, J. F. (2015) 'High-grade gliomas', *CONTINUUM Lifelong Learning in Neurology*, 21(2), pp. 332–344. doi: 10.1212/01.CON.0000464173.58262.d9.
- Hanif, F. *et al.* (2017) 'Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment', *Asian Pacific Journal of Cancer Prevention*, 18(1), pp. 3–9. doi: 10.22034/APJCP.2017.18.1.3.
- Hardiany, N. S., Sadikin, M. and Wanandi, S. I. (2013) 'Eksresi Relatif mRNA Hypoxia Inducible Factor-1? pada Sel Glioma Penderita', *Indonesian Journal of Cancer*. Available at: <http://indonesianjournalofcancer.or.id/e->



journal/index.php/ijoc/article/view/272.

- Hartmann, C. *et al.* (2010) 'Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas', *Acta Neuropathologica*, 120(6), pp. 707–718. doi: 10.1007/s00401-010-0781-z.
- Inskip, P. D. *et al.* (2012) 'Ionizing radiation and the risk of brain and central nervous system tumors : a systematic review', 14(11), pp. 1316–1324.
- Komori, T. (2017) 'The 2016 WHO classification of tumours of the central nervous system: The major points of revision', *Neurologia Medico-Chirurgica*, 57(7), pp. 301–311. doi: 10.2176/nmc.ra.2017-0010.
- Koshy, M. *et al.* (2012) 'Improved survival time trends for glioblastoma using the SEER 17 population-based registries', *Journal of Neuro-Oncology*, 107(1), pp. 207–212. doi: 10.1007/s11060-011-0738-7.
- Ladomersky, E. *et al.* (2019) 'The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma', *Frontiers in Pharmacology*, 10(MAR), pp. 1–13. doi: 10.3389/fphar.2019.00200.
- Lin, Z. *et al.* (2020) 'Establishment of age group classification for risk stratification in glioma patients', *BMC Neurology*. BMC Neurology, 20(1), pp. 1–11. doi: 10.1186/s12883-020-01888-w.
- Lind-Landström, T. *et al.* (2012) 'Prognostic value of histological features in diffuse astrocytomas WHO grade II', *International Journal of Clinical and Experimental Pathology*, 5(2), pp. 152–158.
- Louis, D. N. *et al.* (2007) 'The 2007 WHO classification of tumours of the central nervous system', *Acta Neuropathologica*, 114(2), pp. 97–109. doi: 10.1007/s00401-007-0243-4.
- Louis, D. N. *et al.* (2016) 'The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary', *Acta Neuropathologica*. Springer Berlin Heidelberg, 131(6), pp. 803–820. doi: 10.1007/s00401-016-1545-1.
- M. Kabel, A. *et al.* (2018) 'Astrocytoma: Insights into Risk Factors, Pathogenesis, Diagnosis and Management', *Journal of Cancer Research and Treatment*, 6(3), pp. 70–73. doi: 10.12691/jcrt-6-3-2.
- Malueka, R. G. *et al.* (2020) 'Clinicopathological features and prognosis of Indonesian patients with gliomas with IDH mutation: Insights into its significance in a Southeast Asian population', *Asian Pacific Journal of Cancer Prevention*, 21(8), pp. 2287–2295. doi: 10.31557/APJCP.2020.21.8.2287.
- Merchant, T. E., Pollack, I. F. and Loeffler, J. S. (2010) 'Brain Tumors Across the Age Spectrum: Biology, Therapy, and Late Effects', *Seminars in Radiation*



- Oncology*. Elsevier Inc., 20(1), pp. 58–66. doi: 10.1016/j.semradonc.2009.09.005.
- Ostrom, Q. T. *et al.* (2013) ‘CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010’, *Neuro-Oncology*, 15(SUPPL.2). doi: 10.1093/neuonc/not151.
- Ostrom, Q. T., De Blank, P. M., *et al.* (2014) ‘Alex’s Lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011’, *Neuro-Oncology*, 16, pp. x1–x35. doi: 10.1093/neuonc/nou327.
- Ostrom, Q. T., Bauchet, L., *et al.* (2014) ‘The epidemiology of glioma in adults: A state of the science review’, *Neuro-Oncology*, 16(7), pp. 896–913. doi: 10.1093/neuonc/nou087.
- Ostrom, Q. T., Gittleman, H., Liao, P., *et al.* (2017) ‘CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014’, *Neuro-oncology*, 19(5), pp. v1–v88. doi: 10.1093/neuonc/nox158.
- Ostrom, Q. T., Gittleman, H., Stetson, L., *et al.* (2017) ‘Epidemiology of Intracranial Gliomas’, *Progress in Neurological Surgery*, 30, pp. 1–11. doi: 10.1159/000464374.
- Ostrom, Q. T. *et al.* (2018) ‘Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21’, *Scientific Reports*, 8(1), pp. 1–15. doi: 10.1038/s41598-018-24580-z.
- Padmosantjojo R. M. 2003. 'Brain Tumors in Indonesia', *Proceedings of the 17th Asia Pasific Cancer Congress. Bal. Indonesia*.
- Pollack, I. F., Agnihotri, S. and Broniscer, A. (2019) ‘Childhood brain tumors: Current management, biological insights, and future directions’, *Journal of Neurosurgery: Pediatrics*, 23(3), pp. 261–273. doi: 10.3171/2018.10.PEDS18377.
- Rasmussen, B. K. *et al.* (2017) ‘Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry’, *Journal of Neuro-Oncology*. Springer US, 135(3), pp. 571–579. doi: 10.1007/s11060-017-2607-5.
- Sahm, F. *et al.* (2014) ‘Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma’, *Acta Neuropathologica*, 128(4), pp. 551–559. doi: 10.1007/s00401-014-1326-7.
- Schwartzbaum, J. A. *et al.* (2006) ‘Epidemiology and molecular pathology of glioma’, *Nature Clinical Practice Neurology*, 2(9), pp. 494–503. doi: 10.1038/ncpneuro0289.



- Skjulsvik, A. J. *et al.* (2014) 'Ki-67/MIB-1 immunostaining in a cohort of human gliomas', *International Journal of Clinical and Experimental Pathology*, 7(12), pp. 8905–8910.
- Smetana, K. *et al.* (2016) 'Ageing as an important risk factor for cancer', *Anticancer Research*, 36(10), pp. 5009–5017. doi: 10.21873/anticancerres.11069.
- Theresia, E. *et al.* (2020) 'Association between Ki-67 labeling index and histopathological grading of Glioma in Indonesian population', *Asian Pacific Journal of Cancer Prevention*, 21(4), pp. 1063–1068. doi: 10.31557/APJCP.2020.21.4.1063.
- Weller, M. *et al.* (2015) 'Glioma', *Nature Reviews Disease Primers*, 1(July). doi: 10.1038/nrdp.2015.17.
- Wesseling, P., van den Bent, M. and Perry, A. (2015) 'Oligodendroglioma: pathology, molecular mechanisms and markers', *Acta Neuropathologica*. Springer Berlin Heidelberg, 129(6), pp. 809–827. doi: 10.1007/s00401-015-1424-1.
- Yamanaka, R., Hayano, A. and Kanayama, T. (2018) 'Radiation-induced gliomas: a comprehensive review and meta-analysis', *Neurosurgical Review*. Neurosurgical Review, 41(3), pp. 719–731. doi: 10.1007/s10143-016-0786-8.
- Yan, H. *et al.* (2009) 'Mutations in Gliomas', *New England Journal of Medicine*, 360(8), pp. 765–773. doi: 10.1056/NEJMoa0808710.